<DOC>
	<DOCNO>NCT03065712</DOCNO>
	<brief_summary>This study formally address hypothesis FES-PET/CT measurement ER expression predict clinical benefit first-line endocrine therapy newly diagnose ER+ metastatic breast cancer patient establish repeatability FES PET/CT .</brief_summary>
	<brief_title>Test - Retest Reproducibility 18F Fluoroestradiol ( FES ) PET</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>. Patients must 18 year old capable willing provide inform consent . b . Patients childbearing potential must negative urine serum pregnancy test within 7 day prior PET/CT image per institution 's standard care ; c. A female childbearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion ; . Has undergone hysterectomy bilateral oophorectomy ; ii . Has naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . d. Medically stable judge patient 's physician . e. Life expectancy must estimate &gt; 6 month . f. Patients must ECOG performance status 03 ( restrict ECOG PS 02 age &gt; 70 year ) . g. Patients know allergic hypersensitivity reaction previously administer radiopharmaceutical similar chemical biologic composition FES NOT eligible . h. Patients liver failure NOT eligible . . Patient must NOT breastfeed . j. Histologically confirm metastatic breast cancer k. Primary tumor and/or metastatic site must ER+ may progesteronereceptor positive ( PgR+ ) progesteronereceptor negative ( PgR ) IHC . Patients history estrogenreceptor negative ( ER ) primary tumor document ER+ metastatic site eligible . l. Patients receive molecular target therapy ( everolimus palbociclib ) HER2 direct therapy , addition endocrine therapy NOT eligible . m. Patients history adjuvant endocrine therapy allow , long date diagnosis metastatic disease &gt; 2 year follow initiation adjuvant endocrine therapy . Patients develop metastatic disease still receive adjuvant endocrine therapy must change type endocrine agent use subsequent metastatic disease treatment . Patients block adjuvant therapy ( block agent toremifene tamoxifen ) must agent minimum 60 day allow adequate uptake FES n. Patients human epidermal growth factor2 positive ( HER2+ ) metastatic tumor NOT eligible o. Postmenopausal woman , men , premenopausal woman endocrine therapy alone ( tamoxifen , aromatase inhibitor ( AI ) without ovarian suppression plan standard clinical care , FESPET/CT complete p. Disease may measurable ( RECIST 1.1 criterion ) nonmeasurable must present least one nonliver site , 1.5 cm great visualize PET/CT [ 18F ] fluorodeoxyglucose ( FDG ) . Patients effusion disease disease liver eligible study q . Patient must able lie still 20 30 minute PET/CT scan . Patients meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>PET/CT</keyword>
	<keyword>FES</keyword>
	<keyword>18F Fluoroestradiol</keyword>
	<keyword>Breast</keyword>
</DOC>